Pioglitazone insulin sensitivity and type 2 diabetes mellitus: recent data

被引：6
|
作者：
Monnier, L [1 ]
Sauvanet, JP
机构：
[1] CHU Montpellier, Hop Lapeyronie, Serv Maladies Metab, Montpellier, France
[2] Hop St Louis, Policlin Med Interne, Paris, France
来源：
ANNALES D ENDOCRINOLOGIE | 2004年 / 65卷 / 02期
关键词：
type 2 diabetes mellitus; pioglitazone; beta-pancreatic cell; cardiovascular prevention; cardiovascular morbi-mortality;
D O I：
10.1016/S0003-4266(04)95662-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Thiazolidinediones ("glitazones") were recently added to the oral treatment of type 2 diabetes. Two glitazones are available in France, pioglitazone and rosiglita-zone, which progressively were granted broader therapeutic indications since their launch in 2002. This review presents the most recent pioglitazone pharmacological and clinical data, with a particular emphasis on the QUARTET clinical study program results. Available information generates perspectives and hopes: prevention of the progressive decline in P-pancreatic cell function (and possibly, prevention of type 2 diabetes in at-risk subjects), cardiovascular prevention in type 2 diabetic patients depending on the results of the ongoing prospective morbi-mortality studies in high risk type 2 diabetic patients.
引用
收藏
页码：136 / 148
页数：13
相关论文
共 50 条
  • [1] Pioglitazone enhances insulin sensitivity in patients with Type 2 diabetes mellitus.
    Pavo, I
    Herz, M
    Tan, M
    Shestakova, MV
    Smirnova, OM
    Jermendy, G
    Kerenyi, Z
    Widel, MH
    Schluchter, BJ
    Johns, D
    [J]. DIABETOLOGIA, 2002, 45 : A250 - A250
  • [2] Dose-response effect of pioglitazone on insulin sensitivity in type 2 diabetes mellitus
    Miyazaki, Y
    Bawa, N
    Defronzo, RA
    [J]. DIABETES, 2001, 50 : A126 - A126
  • [3] Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus
    Roden, M
    Laakso, M
    Johns, D
    Widel, M
    Urquhart, R
    Richardson, C
    Mariz, S
    Tan, MH
    [J]. DIABETIC MEDICINE, 2005, 22 (08) : 1101 - 1106
  • [4] Pioglitazone for type 2 diabetes mellitus
    Richter, B.
    Bandeira-Echtler, E.
    Bergerhoff, K.
    Clar, C.
    Ebrahim, S. H.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (04):
  • [5] Predictors of insulin sensitivity in Type 2 diabetes mellitus
    Bonora, E
    Targher, G
    Alberiche, M
    Formentini, G
    Calcaterra, F
    Lombardi, S
    Marini, F
    Poli, M
    Zenari, L
    Raffaelli, A
    Perbellini, S
    Zenere, MB
    Saggiani, F
    Bonadonna, RC
    Muggeo, M
    [J]. DIABETIC MEDICINE, 2002, 19 (07) : 535 - 542
  • [6] The Mechanisms by Which Pioglitazone Improves Insulin Sensitivity and Increases Body Weight in Patients with Type 2 Diabetes Mellitus
    Hirai, Hiroyuki
    Satoh, Hiroaki
    Kudoh, Akihiro
    Hasegawa, Koji
    Yamazaki, Satoru
    Sugaya, Yoshiyuki
    Fujiwara, Makoto
    Honma, Miyuki
    Nakajima, Shinichi
    Midorikawa, Sanae
    Watanabe, Tsuyoshi
    [J]. DIABETES, 2009, 58 : A360 - A360
  • [7] Pioglitazone in the Treatment of Diabetes Mellitus Type 2
    Zach, Herwig
    [J]. JOURNAL FUR HYPERTONIE, 2011, 15 (04): : 58 - 58
  • [8] Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM)
    Miyazaki, Y
    Mahankali, A
    Matsuda, M
    Mahankali, S
    Cusi, K
    Mandarino, L
    Defronzo, RA
    [J]. DIABETES, 2000, 49 : A299 - A299
  • [9] Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes
    Miyazaki, Y
    Matsuda, M
    DeFronzo, RA
    [J]. DIABETES CARE, 2002, 25 (03) : 517 - 523
  • [10] The case history: Combination therapy of the Type-2-Diabetes mellitus with Insulin and Pioglitazone
    Lundershausen, Rainer
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2008, 3 (03) : 146 - 147
12345